Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk <i>NPM1</i>-mutated AMLOnyee Chan, Jeffrey E. Lancet, Somedeb Ball et al.|Blood Advances|2024Cited by 31
Secondary AML Mutations Confer Poor Prognosis in Patients with ELN Favorable Risk <i>NPM1</i>-Mutated AMLOnyee Chan, Jeffrey E. Lancet, Najla Al Ali et al.|Blood|2022Cited by 2